CREBBP and chronic myelogenous leukemia, BCR-ABL1 positive: PRI-724 (also known as ICG-001), that antagonizes Wnt/β-catenin/TCF-mediated transcription and specifically binds to CREB-binding protein (CBP) [99] has been evaluated in a phase 2 study in patients with advanced myeloid malignancies, including CP CML patients with failure of 2 TKIs (where PRI-724 has been administered in combination with dasatinib).